Loading...
Dual pathway inhibition with faricimab for previously treated neovascular age related macular degeneration and diabetic macular oedema: guidance from a UK panel of retina specialists
Downey, Louise Sivaprasad, Sobha Chhabra, Romi R Bailey, Clare Chakrabarti, Soma Lotery, Andrew Patel, Jignesh Silvestri, Julie Watson, Sarah-Lucie Williams, Gwyn
Downey, Louise
Sivaprasad, Sobha
Chhabra, Romi R
Bailey, Clare
Chakrabarti, Soma
Lotery, Andrew
Patel, Jignesh
Silvestri, Julie
Watson, Sarah-Lucie
Williams, Gwyn
Abstract
Conference abstract P121 of The Royal College of Ophthalmologists Annual Congress 2024, 20-23 May, Belfast, UK.
MIDER Authors
Affiliations
Hull Royal Infirmary; Moorfields Eye Hospital NHS Foundation Trust, London; Manchester Royal Eye Hospital; University of Manchester; University Hospitals Bristol and Weston NHS Foundation Trust; NHS Greater Glasgow & Clyde; University of Southampton; Colchester District General Hospital; Royal Victoria Hospital, Belfast; Royal Berkshire NHS Foundation Trust; Swansea Bay University Health Board; South Warwickshire University NHS Foundation Trust; Roche Products Ltd, Welwyn Garden City
Date
2024-11-19
Type
Conference Output
Collections
Citation
Downey L, Sivaprasad S, Chhabra RR, Bailey C, Chakrabarti S, Lotery A, Patel J, Silvestri J, Watson S-L, Williams G, Elsherbiny S, Khokhar S, Parker A. P121 Dual pathway inhibition with faricimab for previously treated neovascular age related macular degeneration and diabetic macular oedema: Guidance from a UK panel of retina specialists. Eye (Lond). 2024 Nov;38(Suppl 3):160-161. doi: 10.1038/s41433-024-03254-3.